Combination therapy in pediatric bronchitis: Examining mucolytic, bronchodilator and anti-inflammatory drug effects on secretion management and recovery time

This study investigated the effectiveness of combining mucolytic agents (ambroxol hydrochloride), bronchodilators (terbutaline sulfate), and anti-inflammatory drugs (budesonide) in treating pediatric bronchitis. From September 2023 to February 2024, 410 pediatric patients were divided into two groups: A control group treated with bronchodilators and anti-inflammatory drugs, and a study group receiving the combined therapy. The results indicated that the study group exhibited significantly better clinical efficacy, with faster resolution of symptoms such as dyspnea, cough, and fever compared to the control group (P0.05). The findings suggest that the combined therapy of mucolytic agents, bronchodilators and anti-inflammatory drugs is highly effective in treating pediatric bronchitis, offering significant benefits in symptom improvement, pulmonary function enhancement, inflammatory reduction, sleep improvement, and airway clearance.